Literature DB >> 6734027

Stereoselective clearance and distribution of intravenous propranolol.

L S Olanoff, T Walle, U K Walle, T D Cowart, T E Gaffney.   

Abstract

Our objective was to determine the kinetics of (+)- and (-)-propranolol after intravenous doses of racemic drug. Five normal subjects received 0.1 mg/kg of a pseudoracemate of propranolol that consisted of deuterium-labeled (+)-propranolol and unlabeled (-)-propranolol. Plasma concentrations of (+)- and (-)-propranolol as measured by gas chromatography-mass spectrometry demonstrated enantiomeric differences in systemic clearance (Cls) [(+)-propranolol, 1.21 +/- 0.15 l/min; (-)-propranolol, 1.03 +/- 0.12 l/min; P less than 0.01] and apparent volume of distribution (Vd) [(+)-propranolol, 4.82 +/- 0.34 l/kg; (-)-propranolol, 4.08 +/- 0.33 l/kg; P less than 0.001], but no difference in distribution or elimination t1/2s (t1/2 beta 3.5 hr). The higher Cls of (+)-propranolol suggests stereoselective hepatic elimination. The higher apparent Vd of (+)-propranolol is mainly related to its lower plasma binding [(+)-propranolol, 20.3 +/- 0.8% unbound; (-)-propranolol, 17.6 +/- 0.7% unbound; P less than 0.001]. There was no stereoselective uptake by red blood cells. These findings demonstrate that multiple stereoselective mechanisms are involved in the disposition of propranolol and determine the access of the drug to active sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734027     DOI: 10.1038/clpt.1984.107

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

2.  Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.

Authors:  B Langner; B Lemmer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Stereoselective binding of propranolol in the elderly.

Authors:  P Colangelo; M Chandler; R Blouin; P McNamara
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

4.  Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.

Authors:  L Borgström; L Nyberg; S Jönsson; C Lindberg; J Paulson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

5.  A high-performance liquid chromatographic assay for the enantiomers of bevantolol in human plasma.

Authors:  S E Rose; E J Randinitis
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

6.  The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans.

Authors:  T Lavé; S Dupin; C Schmitt; B Valles; G Ubeaud; R C Chou; D Jaeck; P Coassolo
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

7.  Stereoselective binding of 11C-raclopride in living human brain--a search for extrastriatal central D2-dopamine receptors by PET.

Authors:  L Farde; S Pauli; H Hall; L Eriksson; C Halldin; T Högberg; L Nilsson; I Sjögren; S Stone-Elander
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man.

Authors:  P Karlsson; G Sedvall; C Halldin; C G Swahn; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

9.  Stereoselective ring oxidation of propranolol in man.

Authors:  T Walle; U K Walle; M J Wilson; T C Fagan; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

10.  Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers.

Authors:  W Krause; G Kühne; N Sauerbrey
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.